Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Alvotech Has Settled With Johnson & Johnson For Certain Markets For AVT04, A Biosimilar To Stelara (Ustekinumab), Market Entry Of AVT04 In Canada Is Expected In Q1 2024, With May 2024 For Japan, And Later July 2024 For First European Markets

Author: Benzinga Newsdesk | February 15, 2024 07:38am

Regulatory approval for AVT04 in these markets has already been granted. Market applications for AVT04 are currently pending in additional global markets, including in the U.S.

Posted In: ALVO JNJ


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist